New Single-Use Pall® XRS 20 Bioreactor System Enhances Cell Culture Performance in Biotechnology Applications
Next-Generation 'Rocker' Bioreactor is Ideal for Suspension Cultures for Life Sciences Applications Up to Full GMP Production
PORT WASHINGTON, N.Y.--(BUSINESS WIRE)-- Pall Corporation (NYSE:PLL), a global leader in filtration, separation and purification, today introduced the XRS 20 Bioreactor System, a new bioreactor with unique agitation properties that incorporates a single-use, easy-to-use Allegro™ 3D biocontainer. This next generation 'rocker' bioreactor, designed for cultivation of mammalian cells in suspension culture, is equally suitable for applications ranging from general life sciences research to seed train operations and full Good Manufacturing Practice (GMP) production at the 2-to-20 liter scale.
The Pall XRS 20 Bioreactor System's unique bi-axial agitation properties improve cell culture performance. (Photo: Business Wire)
The XRS 20 System's unique bi-axial agitation promotes better mixing and higher mass transfer, which expedites transport of nutrients and metabolites in the cellular micro-environment. This allows cultures to reach higher densities with overall greater viabilities, leading to significantly higher protein expression levels.
To ensure operational simplicity, the system includes the following features:
- Allegro XRS 20 biocontainer with integrated components (sensors, filters, drain and tubing sets) for rapid installation and efficient harvesting
- Advanced XRS 20 controller with touchscreen interface for easy monitoring and control of process parameters
A fully enclosed XRS 20 platform with interlock provides operator safety while protecting sensitive media components from light.
"The versatile, easy-to-use XRS 20 Bioreactor System combines state-of-the-art, single-use technology with advanced controls and features that improve cell culture performance," said Ken Frank, President, Pall BioPharmaceuticals.
To learn more about the XRS 20 Bioreactor System please visit www.pall.com/bioreactors.
Pall Life Sciences
Pall Life Sciences provides cutting-edge products and services to meet the demanding needs of customers discovering, developing and producing biotech drugs, vaccines and classic pharmaceuticals. The company's membranes and membrane devices optimize detection and sample preparation in the drug research, clinical diagnostics, genomics, and proteomics markets. Pall is a leading provider of separation systems and single-use filtration and purification technologies to pharmaceutical and biotechnology companies to support faster development of new drugs and vaccines that are safer and require less energy and water to produce. Pall technologies are also used in clinical institutions and the food and beverage industries.
About Pall Corporation
Pall Corporation (NYSE:PLL) is a filtration, separation and purification leader providing solutions to meet the critical fluid management needs of customers across the broad spectrum of life sciences and industry. Pall works with customers to advance health, safety and environmentally responsible technologies. The Company's engineered products enable process and product innovation and minimize emissions and waste. Pall Corporation is an S&P 500 company serving customers worldwide. Pall has been named a "top green company" by Newsweek magazine. To see how Pall is helping enable a greener, safer, more sustainable future, follow us on Twitter @PallCorporation or visit www.pall.com/green.
Senior Marketing Communications Manager
Telephone: +44 (0)2392 303733
KEYWORDS: United States North America New York
The article New Single-Use Pall® XRS 20 Bioreactor System Enhances Cell Culture Performance in Biotechnology Applications originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.